Albireo Pharma (NASDAQ:ALBO) Rating Reiterated by HC Wainwright

HC Wainwright restated their buy rating on shares of Albireo Pharma (NASDAQ:ALBO) in a research report sent to investors on Wednesday, AnalystRatings.com reports. The brokerage currently has a $62.00 price target on the biopharmaceutical company’s stock.

Other equities research analysts have also issued reports about the stock. Wedbush set a $69.00 price objective on shares of Albireo Pharma and gave the company a buy rating in a report on Thursday, May 23rd. Zacks Investment Research lowered shares of Hess Midstream Partners from a hold rating to a sell rating in a report on Tuesday, May 14th. William Blair reaffirmed an outperform rating on shares of Albireo Pharma in a report on Thursday, May 9th. BidaskClub raised shares of Viacom from a sell rating to a hold rating in a report on Friday, July 5th. Finally, ValuEngine lowered shares of Zumiez from a hold rating to a sell rating in a report on Tuesday, July 2nd. One analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $54.25.

Albireo Pharma stock opened at $28.43 on Wednesday. The business has a 50 day moving average price of $32.15. Albireo Pharma has a 12-month low of $19.10 and a 12-month high of $38.69.

Albireo Pharma (NASDAQ:ALBO) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.37) by ($0.02). Albireo Pharma had a negative net margin of 2,900.81% and a negative return on equity of 47.03%. The company had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $1.20 million. As a group, analysts predict that Albireo Pharma will post -5.99 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of ALBO. Federated Investors Inc. PA boosted its position in shares of Albireo Pharma by 22.8% during the 1st quarter. Federated Investors Inc. PA now owns 719,595 shares of the biopharmaceutical company’s stock valued at $23,178,000 after acquiring an additional 133,449 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Albireo Pharma by 40.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 116,223 shares of the biopharmaceutical company’s stock valued at $2,850,000 after acquiring an additional 33,390 shares during the last quarter. Marshall Wace North America L.P. bought a new position in shares of Albireo Pharma during the 1st quarter valued at approximately $816,000. Chicago Capital LLC boosted its position in shares of Albireo Pharma by 6.8% during the 2nd quarter. Chicago Capital LLC now owns 202,241 shares of the biopharmaceutical company’s stock valued at $6,520,000 after acquiring an additional 12,833 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Albireo Pharma by 11.3% during the 4th quarter. Geode Capital Management LLC now owns 97,434 shares of the biopharmaceutical company’s stock valued at $2,390,000 after acquiring an additional 9,922 shares during the last quarter. Hedge funds and other institutional investors own 70.41% of the company’s stock.

About Albireo Pharma

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Featured Article: Oversold

Analyst Recommendations for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.